-
公开(公告)号：US10072025B2
公开(公告)日：2018-09-11
申请号：US15519740
申请日：2015-10-21
Applicant: Merck Sharp & Dohme Corp.
Inventor： Mark E. Scott , David Guerin , Danielle Molinari , Sam Kattar , Peter Fuller , Christopher Dinsmore , Norman Kong , Yunfeng Bai , Jianmin Fu , Yumei Liu , Zhixiang Zheng
IPC: C07D519/00 , C07D471/04 , A61K31/4545 , A61K31/5377 , A61K31/538 , A61K31/55 , A61K31/553 , A61K31/554 , A61K31/541
CPC classification number: C07D519/00 , A61K31/00 , A61K31/437 , A61K31/444 , A61K31/4545 , A61K31/5377 , A61K31/538 , A61K31/541 , A61K31/55 , A61K31/553 , A61K31/554 , A61P11/06 , A61P19/02 , A61P35/00 , C07D471/04
Abstract: The instant invention provides compounds of Formula (I) which are JAK inhibitors, and as such are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer. The present invention provides novel compounds which are inhibitors of JAKs. The invention also provides a method for the treatment and prevention of JAK-mediated diseases and disorders using the novel compounds, as well as pharmaceutical compositions containing the compounds.
-
公开(公告)号：US09957265B2
公开(公告)日：2018-05-01
申请号：US14778052
申请日：2014-03-19
Applicant: Merck Sharp & Dohme Corp.
Inventor： Christopher Dinsmore , Peter Fuller , David Guerin , Christopher F. Thompson , Qinglin Pu , Mark E. Scott , Jason David Katz , Ravi Kurukulasuriya , Joshua T. Close , Danielle Falcone , Jason Brubaker , Hongbo Zeng , Yunfeng Bai , Jianmin Fu , Norman Kong , Yumei Liu , Zhixiang Zheng
IPC: C07D471/04 , C07D519/00
CPC classification number: C07D471/04 , C07D519/00
Abstract: Provided are compounds of Formula I, a JAK inhibitor, and use thereof for the treatment of JAK-mediated diseases by the application.
-
公开(公告)号：US10059705B2
公开(公告)日：2018-08-28
申请号：US14778055
申请日：2014-03-19
Applicant: Merck Sharp & Dohme Corp.
Inventor： Christopher Dinsmore , Peter Fuller , David Guerin , Jason David Katz , Christopher F. Thompson , Danielle Falcone , Wei Deng , Luis Torres , Hongbo Zeng , Yunfeng Bai , Jianmin Fu , Norman Kong , Yumei Liu , Zhixiang Zheng , Mark E. Scott
IPC: C07D471/04 , C07D519/00
CPC classification number: C07D471/04 , C07D519/00
Abstract: The instant invention provides compounds of formula I which are JAK inhibitors, and as such are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.
-
公开(公告)号：US20160272634A1
公开(公告)日：2016-09-22
申请号：US14778055
申请日：2014-03-19
Applicant: Christopher DINSMORE , Peter FULLER , David GUERIN , Jason David KATZ , Christopher F. THOMPSON , Danielle FALCONE , Wei DENG , Luis TORRES , Hongbo ZENG , Yunfeng BAI , Jianmin FU , Norman KONG , Yumei LIU , Zhixiang ZHENG , Mark E. SCOTT , MERCK SHARP & DOHME CORP.
Inventor： Christopher Dinsmore , Peter Fuller , David Guerin , Jason David Katz , Christopher F. Thompson , Danielle Falcone , Wei Deng , Luis Torres , Hongbo Zeng , Yunfeng Bai , Jianmin Fu , Norman Kong , Yumei Liu , Zhixiang Zheng , Mark E. Scott
IPC: C07D471/04 , C07D519/00
CPC classification number: C07D471/04 , C07D519/00
Abstract: The instant invention provides compounds of formula I which are JAK inhibitors, and as such are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.
Abstract translation: 本发明提供了作为JAK抑制剂的式I化合物，因此可用于治疗JAK介导的疾病如类风湿性关节炎，哮喘，COPD和癌症。
-
公开(公告)号：US09884048B2
公开(公告)日：2018-02-06
申请号：US15531759
申请日：2015-12-10
Applicant: Merck Sharp & Dohme Corp.
Inventor： Phieng Siliphaivanh , Joey Methot , Kathryn Ann Lipford , Danielle Molinari , David L. Sloman , David Witter , Hua Zhou , Christopher Boyce , Xianhai Huang , Jongwon Lim , David Guerin , Ganesh Babu Karunakaran , Raman Kumar Bakshi , Ziping Liu , Jianmin Fu , Zhilong Wan , Wei Liu
IPC: A61K31/437 , A61K31/4545 , A61K31/444 , C07D471/04 , C07D519/00
CPC classification number: A61K31/437 , A61K31/444 , A61K31/4545 , C07D471/04 , C07D519/00
Abstract: The present invention provides a compound of Formula (I) or the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are ERK2 inhibitors. The invention also provides a pharmaceutical composition comprising an effective amount of at least one compound of Formula (I) and a pharmaceutically acceptable carrier. The invention also provides a pharmaceutical composition comprising an effective amount of at least one compound of Formula (I) and an effective amount of at least one other pharmaceutically active ingredient (such as, for example, a chemotherapeutic agent), and a pharmaceutically acceptable carrier.
-
Patent Agency Ranking
公开(公告)号：US09957264B2
公开(公告)日：2018-05-01
申请号：US14778046
申请日：2014-03-19
Applicant: Merck Sharp & Dohme Corp.
Inventor： Matthew Lloyd Childers , Peter Fuller , David Guerin , Jason David Katz , Qinglin Pu , Mark E. Scott , Christopher F. Thompson , Michelle Martinez , Danielle Falcone , Luis Torres , Yongqi Deng , Ravi Kurukulasuriya , Hongbo Zeng , Yunfeng Bai , Norman Kong , Yumei Liu , Zhixiang Zheng
IPC: C07D471/04 , C07D519/00
CPC classification number: C07D471/04 , C07D519/00
Abstract: The instant invention provides compounds of Formula (I) which are JAK inhibitors, and as such are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.
-
公开(公告)号：US09725445B2
公开(公告)日：2017-08-08
申请号：US14778019
申请日：2014-03-19
Applicant: Merck Sharp & Dohme Corp.
Inventor： Matthew Lloyd Childers , Christopher Dinsmore , Peter Fuller , David Guerin , Jason David Katz , Qinglin Pu , Mark E. Scott , Christopher F. Thompson , Hongjun Zhang , Danielle Falcone , Luis Torres , Jason Brubaker , Hongbo Zeng , Jiaqiang Cai , Xiaoxing Du , Chonggang Wang , Yunfeng Bai , Norman Kong , Yumei Liu , Zhixiang Zheng
IPC: C07D471/04 , C07D519/00
CPC classification number: C07D471/04 , C07D519/00
Abstract: Compounds of formula I are provided, which are JAK inhibitors and are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.
-
8.发明申请CYCLOALKYL NITRILE PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS 有权甘氨酸激酶抑制剂CYCLOALKYL NITRILE PYRAZOLO PYRIDONES公开(公告)号：US20160280704A1
公开(公告)日：2016-09-29
申请号：US14778019
申请日：2014-03-19
Applicant: Matthew Lloyd Childers , Christopher Dinsmore , Peter Fuller , David Guerin , Jason David Katz , Qinglin Pu , Mark E. Scott , Christopher F. Thompson , Hongjun Zhang , Danielle Falcone , Luis Torres , Jason Brubaker , Hongbo Zeng , Jiaqiang Cai , Xiaoxing Du , Chonggang Wang , Yunfeng Bai , Norman Kong , Yumei Liu , Zhixiang Zheng , Merck Sharp & Dohme Corp.
Inventor： Matthew Lloyd Childers , Christopher Dinsmore , Peter Fuller , David Guerin , Jason David Katz , Qinglin Pu , Mark E. Scott , Christopher F. Thompson , Hongjun Zhang , Danielle Falcone , Luis Torres , Jason Brubaker , Hongbo Zeng , Jiaqiang Cai , Xiaoxing Du , Chonggang Wang , Yunfeng Bai , Norman Kong , Yumei Liu , Zhixiang Zheng
IPC: C07D471/04 , C07D519/00
CPC classification number: C07D471/04 , C07D519/00
Abstract: Compounds of formula I are provided, which are JAK inhibitors and are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.
-
公开(公告)号：US20170266167A1
公开(公告)日：2017-09-21
申请号：US15531759
申请日：2015-12-10
Applicant: Merck Sharp & Dohme Corp.
Inventor： Phieng Siliphaivanh , Joey Methot , Kathryn Ann Lipford , Danielle Molinari , David L. Sloman , David Witter , Hua Zhou , Christopher Boyce , Xianhai Huang , Jongwon Lim , David Guerin , Ganesh Babu Karunakaran , Raman Kumar Bakshi , Ziping Liu , Jianmin Fu , Zhilong Wan , Wei Liu
IPC: A61K31/437 , C07D519/00 , C07D471/04 , A61K31/4545 , A61K31/444
CPC classification number: A61K31/437 , A61K31/444 , A61K31/4545 , C07D471/04 , C07D519/00
Abstract: The present invention provides a compound of Formula (I) or the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are ERK2 inhibitors. The invention also provides a pharmaceutical composition comprising an effective amount of at least one compound of Formula (I) and a pharmaceutically acceptable carrier. The invention also provides a pharmaceutical composition comprising an effective amount of at least one compound of Formula (I) and an effective amount of at least one other pharmaceutically active ingredient (such as, for example, a chemotherapeutic agent), and a pharmaceutically acceptable carrier.
-
10.发明申请N-(2-CYANO HETEROCYCLYL) PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS 有权N-（2-氰基杂环基）吡唑并吡喃酮作为甘薯激酶抑制剂公开(公告)号：US20160272633A1
公开(公告)日：2016-09-22
申请号：US14778052
申请日：2014-03-19
Applicant: Christopher DINSMORE , Peter FULLER , David GUERIN , Christopher F. THOMPSON , Qinglin PU , Mark E. SCOTT , Jason David KATZ , Ravi KURUKLASURIYA , Joshua T. CLOSE , Danielle FALCONE , Jason BRUDAKER , Hongbo ZENG , Yunfeng BAI , Jianmin FU , Norman KONG , Yumei LIU , Zhixiang ZHENG , MERCK SHARP & DOHME CORP.
Inventor： Christopher Dinsmore , Peter Fuller , David Guerin , Christopher F. Thompson , Qinglin Pu , Mark E. Scott , Jason David Katz , Ravi Kuruklasuriya , Joshua T. Close , Danielle Falcone , Jason Brubaker , Hongbo Zeng , Yunfeng Bai , Jianmin Fu , Norman Kong , Yumei Liu , Zhixiang Zheng
IPC: C07D471/04 , C07D519/00
CPC classification number: C07D471/04 , C07D519/00
Abstract: Provided are compounds of Formula I, a JAK inhibitor, and use thereof for the treatment of JAK-mediated diseases by the application.
-
-
-
-
-
-
-
-
-
Search Results
11
records
(took 0.033 seconds)
